CoChat

A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes

Open access
Guo, Yu, Huang, Lisu, Zhang, Guangshun, Yao, Yanfeng, Zhou, He, Shen, Shu, Shen, Bingqing, Li, Bo, Li, Xin, Zhang, Qian, Chen, Mingjie, Chen, Da, Wu, Jia, Fu, Dan, Zeng, Xinxin, Feng, Mingfang, Pi, Chunjiang, Wang, Yuan, Zhou, Xingdong, Lu, Minmin, Li, Yarong, Fang, Yaohui, Lu, Yun-Yueh, Hu, Xue, Wang, Shanshan, Zhang, Wanju, Gao, Ge, Adrian, Francisco, Wang, Qisheng, Yu, Feng, Peng, Yun, Gabibov, Alexander G., Min, Juan, Wang, Yuhui, Huang, Heyu, Stepanov, Alexey, Zhang, Wei, Cai, Yan, Liu, Junwei, Yuan, Zhiming, Zhang, Chen, Lou, Zhiyong, Deng, Fei, Zhang, Hongkai, Shan, Chao, Schweizer, Liang, Sun, Kun, Rao, Zihe · 2021 · Nature Communications
Cited by 94

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

COVID-19 pandemic caused by SARS-CoV-2 constitutes a global public health crisis with enormous economic consequences. Monoclonal antibodies against SARS-CoV-2 can provide an important treatment option to fight COVID-19, especially for the most vulnerable populations. In this work, potent antibodies binding to SARS-CoV-2 Spike protein were identified from COVID-19 convalescent patients. Among them, P4A1 interacts directly with and covers majority of the Receptor Binding Motif of the Spike Receptor-Binding Domain, shown by high-resolution complex structure analysis. We further demonstrate the binding and neutralizing activities of P4A1 against wild type and mutant Spike proteins or pseudoviruses. P4A1 was subsequently engineered to reduce the potential risk for Antibody-Dependent Enhancement of infection and to extend its half-life. The engineered antibody exhibits an optimized pharmacokinetic and safety profile, and it results in complete viral clearance in a rhesus monkey model of COVID-19 following a single injection. These data suggest its potential against SARS-CoV-2 related diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-22926-2

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 94

Metadata

Authors
Guo, Y., Huang, L., Zhang, G., Yao, Y., Zhou, H., Shen, S., Shen, B., Li, B., Li, X., Zhang, Q., Chen, M., Chen, D., Wu, J., Fu, D., Zeng, X., Feng, M., Pi, C., Wang, Y., Zhou, X., Lu, M., Li, Y., Fang, Y., Lu, Y.-Y., Hu, X., Wang, S., Zhang, W., Gao, G., Adrian, F., Wang, Q., Yu, F., Peng, Y., Gabibov, A. G., Min, J., Wang, Y., Huang, H., Stepanov, A., Zhang, W., Cai, Y., Liu, J., Yuan, Z., Zhang, C., Lou, Z., Deng, F., Zhang, H., Shan, C., Schweizer, L., Sun, K., & Rao, Z.
Venue
Nature Communications
Published
2021-05-11
Volume
12
Issue
1
Pages
2623-2623
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3160207037
Cited by
94
References
27
FWCI
6.29
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes. https://app.cochat.ai/papers/10.1038/s41467-021-22926-2
The paper
Guo, Y., Huang, L., Zhang, G., Yao, Y., Zhou, H., Shen, S., Shen, B., Li, B., Li, X., Zhang, Q., Chen, M., Chen, D., Wu, J., Fu, D., Zeng, X., Feng, M., Pi, C., Wang, Y., Zhou, X., . . . Rao, Z. (2021). A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes. Nature Communications. https://doi.org/10.1038/s41467-021-22926-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.